Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society

Grading of Recommendations, Assessment Development and Evaluation (GRADE) tables were created using a standardized and independent assessment of the efficacy and side effects of treatments with monoclonal anti-bodies (mAb) against calcitonin gene-related peptide (CGRP) or the CGRP receptor for the prevention of migraine.

The aim is to provide support for author groups writing national or regional treatment or management guidelines for migraine prevention.

The results show that all mAb are superior to placebo for the reduction in monthly migraine days (days in which a headache consistent with migraine occurred) in participants with episodic and chronic migraine and there are no major differences between the mAb.

The GRADE evidence summary tables provided will support author groups to write treatment guidelines for the prevention of migraine with mAb.

Click to read the article in Cephalalgia.

Don’t forget to check out all the other IHS Guidelines in the Resources menu.